Search for appropriate treatment strategy using fulvestrant for postmenopausal ER-positive advanced or recurrent breast cancer patients in Japan (JBCRG-C06; Safari)

被引：0
|
作者：
Kawaguchi, H. [1 ,11 ]
Masuda, N. [2 ]
Nakayama, T. [3 ]
Aogi, K. [4 ]
Anan, K. [5 ]
Ito, Y. [6 ]
Ohtani, S. [7 ]
Sato, N. [8 ]
Saji, S. [9 ]
Tokunaga, E. [10 ]
Nakamura, S.
Hasegawa, Y. [12 ]
Hattori, M. [13 ]
Fujisawa, T. [14 ]
Morita, S. [15 ]
Yamaguchi, M. [16 ]
Yamashita, T. [17 ]
Yamamoto, Y. [18 ]
Ohno, S. [19 ]
Toi, M. [20 ]
机构：
[1] Matsuyama Red Cross Hosp, Breast Surg, Matsuyama, Ehime, Japan
[2] Osaka Natl Hosp, Dept Surg Breast Oncol, Osaka, Japan
[3] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Breast & Endocrine Surg, Osaka, Japan
[4] Shikoku Canc Ctr, Dept Breast Oncol, Matsuyama, Ehime, Japan
[5] Kitakyushu Municipal Med Ctr, Dept Surg, Kitakyushu, Fukuoka, Japan
[6] Canc Inst Hosp JFCR, Breast Med Oncol Dept, Tokyo, Japan
[7] Hiroshima City Hiroshima Citizens Hosp, Dept Breast Surg Hiroshima, Hiroshima, Japan
[8] Niigata Canc Ctr Hosp, Dept Breast Oncol, Niigata, Japan
[9] Fukushima Med Univ, Dept Med Oncol, Fukushima, Japan
[10] Kyushu Canc Ctr, Dept Breast Oncol, Fukuoka, Japan
[11] Showa Univ, Sch Med, Showa Univ Hosp, Dept Surg,Div Breast Surg Oncol, Tokyo 142, Japan
[12] Hirosaki Municipal Hosp, Dept Breast Surg, Hirosaki, Aomori, Japan
[13] Aichi Canc Ctr Hosp, Dept Breast Oncol, Nagoya, Aichi 464, Japan
[14] Gunma Prefectural Canc Ctr, Dept Breast Oncol, Ohta, Gunma, Japan
[15] Kyoto Univ, Dept Biomed Stat & Bioinformat, Grad Sch Med, Kyoto, Japan
[16] JCHO Kurume Gen Hosp, Dept Breast Surg, Kurume, Fukuoka, Japan
[17] Komagome Hosp, Dept Breast Surg, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo, Japan
[18] Kumamoto Univ, Grad Sch Med Sci, Dept Breast & Endocrine Surg, Kumamoto, Japan
[19] Canc Inst Hosp JFCR, Breast Oncol Ctr, Tokyo, Japan
[20] Kyoto Univ, Dept Breast Surg, Grad Sch Med, Kyoto, Japan
来源：
EUROPEAN JOURNAL OF CANCER | 2016年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
379
引用
收藏
页码：S109 / S109
页数：1
相关论文
共 48 条
  • [41] Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)
    Toshinari Yamashita
    Norikazu Masuda
    Shigehira Saji
    Kazuhiro Araki
    Yoshinori Ito
    Toshimi Takano
    Masato Takahashi
    Junji Tsurutani
    Kei Koizumi
    Masahiro Kitada
    Yasuyuki Kojima
    Yasuaki Sagara
    Hiroshi Tada
    Tsutomu Iwasa
    Takayuki Kadoya
    Tsuguo Iwatani
    Hiroki Hasegawa
    Satoshi Morita
    Shinji Ohno
    Trials, 21
  • [42] Predicting invasive disease-free survival in ER-positive, HER2-negative early breast cancer using the PAM50 risk-of-recurrence score: a retrospective analysis using single-center long-term follow-up data of postmenopausal Japanese patients
    Higami, Akane
    Takada, Masahiro
    Kawaguchi-Sakita, Nobuko
    Kawashima, Masahiro
    Kawaguchi, Kosuke
    Yamaguchi, Ayane
    Takeuchi, Yasuhide
    Yamada, Yosuke
    Toi, Masakazu
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (11) : 1715 - 1720
  • [43] Using the 21-gene recurrence score and the recently developed Recurrence Score-Clinical-Pathologic to assess recurrence risk in patients with node-negative, ER-positive early-stage breast cancer receiving aromatase inhibitor treatment alone.
    Crager, M.
    Tang, G.
    Shak, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [44] Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD) (vol 21, 391, 2020)
    Yamashita, Toshinari
    Masuda, Norikazu
    Saji, Shigehira
    Araki, Kazuhiro
    Ito, Yoshinori
    Takano, Toshimi
    Takahashi, Masato
    Tsurutani, Junji
    Koizumi, Kei
    Kitada, Masahiro
    Kojima, Yasuyuki
    Sagara, Yasuaki
    Tada, Hiroshi
    Iwasa, Tsutomu
    Kadoya, Takayuki
    Iwatani, Tsuguo
    Hasegawa, Hiroki
    Morita, Satoshi
    Ohno, Shinji
    TRIALS, 2020, 21 (01)
  • [45] Phase III study of ribociclib (LEE011) in combination with fulvestrant for the treatment of postmenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (aBC) who have received no or only one line of prior endocrine treatment: MONALEESA-3
    Fasching, P. A.
    Jerusalem, G.
    Pivot, X.
    Martin, M.
    De Laurentiis, M.
    Blackwell, K.
    Esteva, F. J.
    Paquet-Luzy, T.
    Tang, Z.
    Lorenc, K. R.
    Slamon, D. J.
    CANCER RESEARCH, 2016, 76
  • [46] EPIK-B6: A phase 2, open-label, 2-part, multicenter study of alpelisib in combination with fulvestrant for men and postmenopausal women with PIK3CA mutation HR-positive, HER2-negative, advanced breast cancer, which progressed on/after aromatase inhibitor treatment in Japan
    Iwata, Hiroji
    Niikura, Naoki
    Sueki, Hirohiko
    Aruga, Tomoyuki
    Mukohara, Toru
    Kobayashi, Kokoro
    Yasojima, Hiroyuki
    Nakayama, Takahiro
    Toyama, Tatsuya
    Ishida, Takanori
    Yamashita, Toshinari
    Takahashi, Masato
    Fujii, Takaaki
    El-Hashimy, Mona
    Miller, Michelle Kristine
    Kurihara, Ryohei
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [47] Phase III study of ribociclib (LEE011) plus fulvestrant for the treatment of postmenopausal patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (aBC) who have received no or only one line of prior endocrine treatment (ET). MONALEESA-3.
    Fasching, Peter A.
    Jerusalem, Guy Heinrich Maria
    Pivot, Xavier
    Martin, Miguel
    De laurentiis, Michele
    Blackwell, Kimberly L.
    Esteva, Francisco J.
    Chia, Stephen K. L.
    Germa, Caroline
    Tang, Zhongwen
    Dhuria, Shyeilla V.
    Slamon, Dennis J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [48] A randomized phase II study of PD 0332991, cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole for first-line treatment of patients with postmenopausal, estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer.
    Finn, R. S.
    Boer, K.
    Lang, I.
    Parikh, R. J.
    Patel, R.
    Schmidt, M.
    Hagenstad, C. T.
    Lim, H. J.
    Pinter, T.
    Amadori, D.
    Chan, D.
    Dichmann, R.
    Kim, S. T.
    Randolph, S.
    Slamon, D. J.
    Crown, J. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345